TARGETING BCMA
BCMA expression is largely restricted to plasma cells and is uniquely overexpressed on myeloma cells, making BCMA a promising target antigen.1,2
ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
Watch MOA video
Antigen-specific activation of ABECMA results in CAR-positive T cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells.1
BCMA is expressed both on normal and malignant plasma cells.
TARGETING BCMA
BCMA expression is largely restricted to plasma cells and is uniquely overexpressed on myeloma cells, making BCMA a promising target antigen.1,2
Treatment process includes leukapheresis, manufacturing, administration, and adverse event monitoring. A single dose of ABECMA contains a cell suspension of 300 to 460 x 106 CAR-positive T cells in one or more infusion bags.
BCMA=B-cell maturation antigen; CAR=chimeric antigen receptor; MM=multiple myeloma; MOA=mechanism of action; RRMM=relapsed/refractory multiple myeloma; scFv=single-chain variable fragment.